title: A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo.
abstract: Many antitumor drugs have a limited ability to penetrate more than a few cell diameters from blood vessels into solid tumors, which limits their effectiveness. In this study, we investigated whether the biological activity of endostatin can be enhanced by the addition of an integrin-targeting and permeability-enhancing sequence. The internalization RGD (CRGDKGPDC; iRGD) sequence was added at the carboxyl terminus of endostatin. Modification of endostatin with the iRGD motif showed specific and increased binding to endothelial cells; the increased binding correlated with an improved antiangiogenic property. iRGD-modified endostatin was more effective than human endostatin in inhibiting liver cancer growth in athymic mice. The finding indicates that addition of a vascular targeting and permeability sequence can enhance the biological activity of an antiangiogenic molecule and tumor targeting.
authors.affiliation: Key Laboratory of Molecular Cytogenetics and Genetic Breeding of Heilongjiang Province, College of Life Science and Technology, Harbin Normal University, Harbin, China.
authors.forename: Zhang
authors.initials: Z
authors.lastname: Hai-Tao
authors.forename: Li
authors.initials: L
authors.lastname: Hui-Cheng
authors.forename: Li
authors.initials: L
authors.lastname: Zheng-Wu
authors.forename: Guo
authors.initials: G
authors.lastname: Chang-Hong
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001483:Base Sequence; D002199:Capillary Permeability; D002417:Cattle; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D057846:Cell-Penetrating Peptides / Q000008:administration & dosage / Q000235:genetics / Q000493:pharmacokinetics; D002642:Chick Embryo; D043169:Endostatins / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics*; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006801:Humans; D016023:Integrins / Q000378:metabolism; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics*; D011485:Protein Binding; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000493:pharmacokinetics
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D057846:Cell-Penetrating Peptides; D043169:Endostatins; D016023:Integrins; D009842:Oligopeptides; D011993:Recombinant Fusion Proteins; C047981:arginyl-glycyl-aspartic acid